Neoadjuvant Treatment Adherence Predicts Advanced Rectal Cancer Outcomes
Advanced rectal cancer patients who complete their course of neoadjuvant chemoradiotherapy have better 3-year disease-free survival than those who do not
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Advanced rectal cancer patients who complete their course of neoadjuvant chemoradiotherapy have better 3-year disease-free survival than those who do not
Cabozantinib warrants further investigation in patients with pretreated, metastatic urothelial carcinoma
The optimal method of defining hyperprogressive disease has been reviewed
Maintenance olaparib improves overall survival for BRCA mutation-positive, platinum-sensitive, relapsed ovarian cancer
For women with de novo metastatic breast cancer, early locoregional therapy does not improve overall survival
The selective MET inhibitor tepotinib could benefit up to half of patients with advanced or metastatic non-small-cell lung cancer with a MET exon 14 skipping mutation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.